JBC Anatrace, Inc.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M410312200 on October 14, 2004

J. Biol. Chem., Vol. 279, Issue 53, 55419-55424, December 31, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
279/53/55419    most recent
M410312200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ge, L.
Right arrow Articles by DeFea, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ge, L.
Right arrow Articles by DeFea, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Constitutive Protease-activated Receptor-2-mediated Migration of MDA MB-231 Breast Cancer Cells Requires Both {beta}-Arrestin-1 and -2*{boxs}

Lan Ge{ddagger}§, Sudha K. Shenoy¶§, Robert J. Lefkowitz¶||, and Kathryn DeFea{ddagger}**{ddagger}{ddagger}

From the {ddagger}Division of Biomedical Sciences, **Biochemical and Molecular Biology Program and Cellular, Molecular and Developmental Biology Program, University of California, Riverside, California 92521 and the Howard Hughes Medical Institute, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27710

Protease-activated receptor-2 (PAR-2) is activated by trypsin-like serine proteases and can promote cell migration through an ERK1/2-dependent pathway, involving formation of a scaffolding complex at the leading edge of the cell. Previous studies also showed that expression of a dominant negative fragment of {beta}-arrestin-1 reduces PAR-2-stimulated internalization, ERK1/2 activation, and cell migration; however, this reagent may block association of many proteins, including {beta}-arrestin-2 with clathrin-coated pits. Here we investigate the role of PAR-2 in the constitutive migration of a metastatic breast cancer cell line, MDA MB-231, and use small interfering RNA to determine the contribution of each {beta}-arrestin to this process. We demonstrate that a trypsin-like protease secreted from MDA MB-231 cells can promote cell migration through autocrine activation of PAR-2 and this correlates with constitutive localization of PAR-2, {beta}-arrestin-2, and activated ERK1/2 to pseudopodia. Addition of MEK-1 inhibitors, trypsin inhibitors, a scrambled PAR-2 peptide, and silencing of {beta}-arrestins with small interfering RNA also reduce base-line migration of MDA MB-231 cells. In contrast, a less metastatic PAR-2 expressing breast cancer cell line does not exhibit constitutive migration, pseudopodia formation, or trypsin secretion; in these cells PAR-2 is more uniformly distributed around the cell periphery. These data demonstrate a requirement for both {beta}-arrestins in PAR-2-mediated motility and suggest that autocrine activation of PAR-2 by secreted proteases may contribute to the migration of metastatic tumor cells through {beta}-arrestin-dependent ERK1/2 activation.


Received for publication, September 8, 2004 , and in revised form, October 12, 2004.

* This work was supported by National Institutes of Health Grants R01HL016037 (to R. J. L.) and R01GM066151 (to K. D.) and in part by University of California Breast Cancer Research Program Award 7KB-0093. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

{boxs} The on-line version of this article (available at http://www.jbc.org) contains supplemental video 1.

§ These authors contributed equally to this work.

|| A Howard Hughes Medical Institute Investigator.

{ddagger}{ddagger} To whom all correspondence should be addressed: B605 Statistics Rd., University of California, Riverside, CA 92521. Tel.: 951-827-2871; E-mail: katie.defea{at}ucr.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
B. Lagane, K. Y. C. Chow, K. Balabanian, A. Levoye, J. Harriague, T. Planchenault, F. Baleux, N. Gunera-Saad, F. Arenzana-Seisdedos, and F. Bachelerie
CXCR4 dimerization and {beta}-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome
Blood, July 1, 2008; 112(1): 34 - 44.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. J. Ramsay, Y. Dong, M. L. Hunt, M. Linn, H. Samaratunga, J. A. Clements, and J. D. Hooper
Kallikrein-related Peptidase 4 (KLK4) Initiates Intracellular Signaling via Protease-activated Receptors (PARs): KLK4 AND PAR-2 ARE CO-EXPRESSED DURING PROSTATE CANCER PROGRESSION
J. Biol. Chem., May 2, 2008; 283(18): 12293 - 12304.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. H. Versteeg, F. Schaffner, M. Kerver, H. H. Petersen, J. Ahamed, B. Felding-Habermann, Y. Takada, B. M. Mueller, and W. Ruf
Inhibition of tissue factor signaling suppresses tumor growth
Blood, January 1, 2008; 111(1): 190 - 199.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
T. Bouschet, S. Martin, V. Kanamarlapudi, S. Mundell, and J. M. Henley
The calcium-sensing receptor changes cell shape via a beta-arrestin-1 ARNO ARF6 ELMO protein network
J. Cell Sci., August 1, 2007; 120(15): 2489 - 2497.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Zoudilova, P. Kumar, L. Ge, P. Wang, G. M. Bokoch, and K. A. DeFea
beta-Arrestin-dependent Regulation of the Cofilin Pathway Downstream of Protease-activated Receptor-2
J. Biol. Chem., July 13, 2007; 282(28): 20634 - 20646.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
P. Kumar, C. S. Lau, M. Mathur, P. Wang, and K. A. DeFea
Differential effects of beta-arrestins on the internalization, desensitization and ERK1/2 activation downstream of protease activated receptor-2
Am J Physiol Cell Physiol, July 1, 2007; 293(1): C346 - C357.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. R. Hamilton, S. F. Fard, F. F. Paiwand, C. Tolg, M. Veiseh, C. Wang, J. B. McCarthy, M. J. Bissell, J. Koropatnick, and E. A. Turley
The Hyaluronan Receptors CD44 and Rhamm (CD168) Form Complexes with ERK1,2 That Sustain High Basal Motility in Breast Cancer Cells
J. Biol. Chem., June 1, 2007; 282(22): 16667 - 16680.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
P. Arora, T. K. Ricks, and J. Trejo
Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer
J. Cell Sci., March 15, 2007; 120(6): 921 - 928.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Vroon, C. J. Heijnen, and A. Kavelaars
GRKs and arrestins: regulators of migration and inflammation
J. Leukoc. Biol., December 1, 2006; 80(6): 1214 - 1221.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Jafri, H. M. El-Shewy, M.-H. Lee, M. Kelly, D. K. Luttrell, and L. M. Luttrell
Constitutive ERK1/2 Activation by a Chimeric Neurokinin 1 Receptor-beta-Arrestin1 Fusion Protein: PROBING THE COMPOSITION AND FUNCTION OF THE G PROTEIN-COUPLED RECEPTOR "SIGNALSOME"
J. Biol. Chem., July 14, 2006; 281(28): 19346 - 19357.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. G. H. Scott, V. Pierotti, H. Storez, E. Lindberg, A. Thuret, O. Muntaner, C. Labbe-Jullie, J. A. Pitcher, and S. Marullo
Cooperative Regulation of Extracellular Signal-Regulated Kinase Activation and Cell Shape Change by Filamin A and {beta}-Arrestins.
Mol. Cell. Biol., May 1, 2006; 26(9): 3432 - 3445.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
L. Hunyady and K. J. Catt
Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II
Mol. Endocrinol., May 1, 2006; 20(5): 953 - 970.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. K. Shenoy, M. T. Drake, C. D. Nelson, D. A. Houtz, K. Xiao, S. Madabushi, E. Reiter, R. T. Premont, O. Lichtarge, and R. J. Lefkowitz
beta-Arrestin-dependent, G Protein-independent ERK1/2 Activation by the beta2 Adrenergic Receptor
J. Biol. Chem., January 13, 2006; 281(2): 1261 - 1273.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. R. Morris, Y. Ding, T. K. Ricks, A. Gullapalli, B. L. Wolfe, and J. Trejo
Protease-Activated Receptor-2 Is Essential for Factor VIIa and Xa-Induced Signaling, Migration, and Invasion of Breast Cancer Cells
Cancer Res., January 1, 2006; 66(1): 307 - 314.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
S. K. Shenoy and R. J. Lefkowitz
Seven-Transmembrane Receptor Signaling Through {beta}-Arrestin
Sci. Signal., November 1, 2005; 2005(308): cm10 - cm10.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
R. J. Lefkowitz and S. K. Shenoy
Transduction of Receptor Signals by {beta}-Arrestins
Science, April 22, 2005; 308(5721): 512 - 517.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.